David B. Jackson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David B. Jackson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Picker
LIFE Biosystems GmbH, Belfortstr. 2, Heidelberg 69115, Germany
1 shared publication - Andrey Loboda
Merck & Co., Inc. 7 Boston, MA
1 shared publication - Carolyne A Buser
Merck Research Laboratories, North Wales, USA
1 shared publication - Deepak Agrawal
Moffitt Cancer Center, Tampa, USA
1 shared publication - Hongyue Dai
Merck Research Laboratories, Merck & Co., Inc., Boston, MA, USA
1 shared publication - James Watters
Merck, Sharp and Dohme, West Point, USA
1 shared publication
Latest Publications
- 1 July 2011
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 11 (6) , 567-577
Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine
While current trials of anticancer agents serve to provide a population-based validation of therapeutic activity, clinical success is typically restricted to tumors of select molecular subtype. Recent insights have yielded a growing catalogue of germline and tumor-based aberrations that can predetermine whether a patient will achieve clinical benefit from a drug or not. Thus, in order to realize the true potential of anticancer agents, we need to define the molecular contexts under which they will prove both efficacious and safe. In this article, we provide an overview of such molecular determinants and introduce the concept of 'cancer patient profiling' - the process and science of defining the optimal therapy for a given patient through the generation and analysis of system-wide molecular information.
- 1 July 2011
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 11 (6) , 567-577
Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine
While current trials of anticancer agents serve to provide a population-based validation of therapeutic activity, clinical success is typically restricted to tumors of select molecular subtype. Recent insights have yielded a growing catalogue of germline and tumor-based aberrations that can predetermine whether a patient will achieve clinical benefit from a drug or not. Thus, in order to realize the true potential of anticancer agents, we need to define the molecular contexts under which they will prove both efficacious and safe. In this article, we provide an overview of such molecular determinants and introduce the concept of 'cancer patient profiling' - the process and science of defining the optimal therapy for a given patient through the generation and analysis of system-wide molecular information.
- Open Access
- 20 January 2011
- Published by Springer Nature in BMC Medical Genomics
- Vol. 4 (1) , 1-10
EMT is the dominant program in human colon cancer
Background: Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging. Methods: We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular subtypes of colon cancer that predicted disease progression and recurrence. Results: Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was tightly correlated (Pearson R = 0.92, P < 10-135) with the EMT signature-- both in gene identity and directionality. In a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to regulate EMT. Conclusions: These data demonstrate that the biology underpinning the native, molecular classification of human colon cancer--previously thought to be highly heterogeneous-- was clarified through the lens of comprehensive transcriptome analysis.
- 20 January 2011
- Published by Springer Nature in BMC Medical Genomics
- Vol. 4 (1) , 1-10
Open AccessEMT is the dominant program in human colon cancer
Background: Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging. Methods: We performed an unsupervised analysis of microarray data from 326 colon cancers to identify the first principal component (PC1) of the most variable set of genes. PC1 deciphered two primary, intrinsic molecular subtypes of colon cancer that predicted disease progression and recurrence. Results: Here we report that the most dominant pattern of intrinsic gene expression in colon cancer (PC1) was tightly correlated (Pearson R = 0.92, P < 10-135) with the EMT signature-- both in gene identity and directionality. In a global micro-RNA screen, we further identified the most anti-correlated microRNA with PC1 as MiR200, known to regulate EMT. Conclusions: These data demonstrate that the biology underpinning the native, molecular classification of human colon cancer--previously thought to be highly heterogeneous-- was clarified through the lens of comprehensive transcriptome analysis.
- 1 April 2009
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (7-8) , 380-385
Clinical and economic impact of the nonresponder phenomenon – implications for systems based discovery
- 1 April 2009
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (7-8) , 380-385
Clinical and economic impact of the nonresponder phenomenon – implications for systems based discovery
- 1 April 2009
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (7-8) , 373-379
Molecular perspectives on the non-responder phenomenon
- 1 April 2009
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (7-8) , 373-379
Molecular perspectives on the non-responder phenomenon
- 6 January 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (1) , E5
Serum-based microRNAs: Are we blinded by potential?
- 6 January 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (1) , E5
Serum-based microRNAs: Are we blinded by potential?